Announcements Trials
Browse Landscape

Phase

Phase 2 35Phase 1/2 18Phase 1 16Phase EARLY_PHASE1 3Phase 3 3

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 6Breast 6Thoracic 5Head & Neck 5Gastrointestinal 5Lymphoid 4Sarcoma 3Gynecologic 3Other hematologic neoplasm 2Genitourinary 2Plasma cell 1Myeloid 1CNS 1

Conditions

Sarcoma 3Squamous Cell Carcinoma of Head and Neck 2Head and Neck Neoplasms 2Melanoma 1Lymphoma 1

Interventions

Magnetic Resonance Spectroscopy 6pembrolizumab 3Specimen Handling 3Radiotherapy 3Oncolytic Virotherapy 3Nivolumab 3Irinotecan 3Cyclophosphamide 3X-Rays 2Temozolomide 2Etoposide 2Doxorubicin 2Biopsy 2Bevacizumab 2trastuzumab biosimilar HLX02 1sodium thiosulfate 1romiplostim 1pertuzumab 1perflutren 1palbociclib 1olaparib 1niraparib 1montelukast 1glucarpidase 1gamma-Glutamyl Hydrolase 1fluorodopa F 18 1eribulin 1entrectinib 1entacapone 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × pembrolizumab × Sarcoma × Clear all
NCT04541108 2026-05-22

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Presage Biosciences

Phase EARLY_PHASE1 Active not recruiting
15 enrolled
DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT05488366 2025-09-22

Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma

University of California, Irvine

Phase EARLY_PHASE1 Active not recruiting
9 enrolled
Sarcoma

Sarcoma

NCT06413095 2024-05-14

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

Presage Biosciences

Phase EARLY_PHASE1 Completed
13 enrolled
Head & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡